# Hyku Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hyku-biosciences

- Industry: Biotechnology
- Headquarters: Lexington, US
- Website: www.hykubiosciences.com
- Total disclosed funding: $56M
- Latest round: Seed (Sep 19, 2023)
- Investors on record: 6

## About

Based in Massachusetts, US, and founded by Milind Deshpande, Hyku Biosciences, Inc. operates as a research and development medical company that finds substances that covalently link non-cysteine amino acids to create novel treatments for diseases like cancer. In September 2023, Hyku Biosciences, Inc. raised USD 56 million in seed funding co-led by investors RA Capital Management, Droia Ventures, and Novartis Venture Fund, with participation from investors The Mark Foundation for Cancer Research, KB Investment, and Eisai Innovation.

The company offers a proprietary Hyku platform, which identifies and leverages compounds capable of covalently binding to non-cysteine amino acids. This enables the development of novel therapies that address the inherent challenges associated with numerous disease targets, including issues related to selectivity, druggability, and resistance. Through rigorous scientific exploration and an unwavering commitment to progress, Hyku has become a leading force in the quest to transform conventional treatment paradigms. This multidisciplinary approach enables the company to identify and develop small-molecule therapeutics against a diverse range of drug targets, ultimately aimed at improving patient lives.

The company plans to use the September 2023 funding to create precise molecular bond therapeutics for cancer.

## Funding rounds

- Seed, Sep 19, 2023, $56M — Novartis Venture Fund, KB Investment, RA Capital Management, Droia Ventures, Mark Foundation for Cancer Research, Eisai Innovation

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Seed
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Seed
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Seed
- Droia Ventures (https://capitalatlas.ai/funds/droia-ventures) — Seed
- Mark Foundation for Cancer Research — Seed
- Eisai Innovation (https://capitalatlas.ai/funds/eisai-innovation) — Seed